Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in Human Immunodeficiency Virus (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

NCT02607956 PHASE3 COMPLETED Results posted

This primary objective of this study is to evaluate the efficacy of a fixed dose combination (FDC) containing bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) versus dolutegravir (DTG) + a FDC containing emtricitabine/tenofovir alafenamide (F/TAF) in HIV-1 infected, antiretroviral treatment-naive adults.

Details

Lead sponsor	Gilead Sciences
Phase	PHASE3
Status	COMPLETED
Enrolment	657
Start date	Wed Nov 11 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Mon Jul 05 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• HIV-1 Infection

Interventions

• DTG
• F/TAF
• B/F/TAF
• DTG Placebo
• F/TAF Placebo
• B/F/TAF Placebo

Countries

France, Italy, Dominican Republic, Belgium, United Kingdom, Germany, Canada, Puerto Rico, Australia, United States, Spain